LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

29.33 -1.11

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

29.1

Max

30.27

Belangrijke statistieken
By Trading Economics
Inkomsten	2.6M -79M
Verkoop	-60K 15K
EPS	-1.18
Winstmarge	-524,566.667
Werknemers	198
EBITDA	-3M -84M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+68.92% upside

Dividenden
By Acuity
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-330M 2.2B
Vorige openingsprijs	30.44
Vorige sluitingsprijs	29.33

Nieuwssentiment

By Acuity

100%

320 / 344 Rangschikking in Healthcare

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jun 2026, 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

10 jun 2026, 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 jun 2026, 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 jun 2026, 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 jun 2026, 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

10 jun 2026, 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

10 jun 2026, 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 jun 2026, 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 jun 2026, 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 jun 2026, 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 jun 2026, 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 jun 2026, 23:38 UTC

Global Equities Roundup: Market Talk

10 jun 2026, 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

10 jun 2026, 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 jun 2026, 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 jun 2026, 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 jun 2026, 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

10 jun 2026, 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 jun 2026, 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

10 jun 2026, 20:50 UTC

Financial Services Roundup: Market Talk

10 jun 2026, 20:50 UTC

Basic Materials Roundup: Market Talk

10 jun 2026, 20:50 UTC

Health Care Roundup: Market Talk

10 jun 2026, 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 jun 2026, 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 jun 2026, 20:33 UTC

Global Equities Roundup: Market Talk

10 jun 2026, 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

68.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 50 USD 68.92%

Hoogste 67 USD

Laagste 38 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.